Enovis Corp
(FRA:C520)
€
21.8
+1.4 (+6.86%)
Market Cap: 1.30 Bil
Enterprise Value: 2.51 Bil
PE Ratio: 0
PB Ratio: 1.00
GF Score: 64/100 Enovis Corp at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023 / 03:40PM GMT
Release Date Price:
€53.5
(+0.94%)
Jamie Aaron Perse
Goldman Sachs Group, Inc., Research Division - Associate
Good morning, everyone. I'm Jamie Perse. Thank you for joining Day 2 of the Goldman Healthcare Conference. Our next panel is with Enovis. We have CEO, Matt Trerotola, CFO, Ben Berry; and in the audience, we've got IR, Derek Leckow. Thank you for joining.
Matthew L. Trerotola
Enovis Corporation - CEO & Chairman
Thank you. Great to be here. Thanks.
Questions & Answers
Jamie Aaron Perse
Goldman Sachs Group, Inc., Research Division - Associate
Maybe we could start, I mean, I think investors are still getting up to speed on the company, and maybe you could just say a few words about the high-level story and where you guys are at today?
Matthew L. Trerotola
Enovis Corporation - CEO & Chairman
Yes, sure. Thanks. We're a focused med tech innovation-driven growth company, a little over $1.5 billion of revenues. We were created a little over a year ago by a separation from Colfax,
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot